United States: The Trans-Pacific Partnership And Its Potential Impact On Exclusivity Periods For Biological Products

After five years of negotiations, the twelve member countries of the Trans-Pacific Partnership (TPP) agreement have reached consensus on its general terms. While the TPP encompasses a broad array of trade-related issues, exclusivity periods for biological products was one of the most controversial issues, and, according to reports, was the "final sticking point" before coming to an actual agreement.1

In the United States, the Biologics Price Competition and Innovation Act (BPCIA) provides a twelve-year period of exclusivity for biologics. Similarly, the European Union, though not involved in the TPP, has a ten-year term of protection for biologics, made up of eight years of data exclusivity and two years of marketing exclusivity.2 During the negotiations, the U.S. trade representative proposed twelve years of exclusivity, mirroring the BPCIA. Australia, however, led opposition to the U.S. proposal and instead fought for a five-year period, which reflects its domestic law.3 Among the TPP member countries, the United States has the longest period of biologics exclusivity, followed by Japan and Canada, both providing eight years. By contrast, the remaining countries, including Chile, Malaysia, New Zealand, and Singapore, provide five or fewer years of data exclusivity, and Brunei, Mexico, Peru, and Vietnam do not grant exclusivity periods for biologics. 4,5,6,7

According to reports and leaked texts, the TPP sets forth two possible market exclusivity schemes for biologics. Under the first option, parties must provide eight years of regulatory data protection for new biologics, beginning on the date of first marketing approval.8 Under the second option, parties must "deliver a comparable outcome in the market" through a five-year period of regulatory data protection and "other measures."9 In effect, the second option appears to formally require only a five-year period of data exclusivity. Statements by Australia's trade minister reinforce that interpretation, as he has said that Australia will not need to change its laws to comply with the TPP biologics provisions.10 The TPP, as currently proposed, mandates minimum protections for biologics, but does not set a maximum term. Therefore, a country might still comply with the TPP even if its exclusivity period is greater than five years.11

Even though the twelve member countries reached a consensus, implementation of the TPP in the United States is far from a certainty. Like other U.S. trade agreements, the TPP is treated as a congressional-executive agreement rather than a treaty.12 As a result, the President and his trade representative may negotiate the agreement, but it has legal force only if it is approved by Congress.13 However, Congress does not vote on the actual TPP; rather it must approve "implementing legislation." Implementing legislation contains provisions that amend existing and create new U.S. federal laws in order to comply with the TPP.14

The 2015 Trade Promotion Authority (TPA) dictates most of the procedural steps for implementation of the TPP. Once the text of the TPP is finalized, the TPA requires the President give Congress 90 days' notice before signing the agreement. Once the President has signed the agreement, he must draft the implementing legislation and submit it to Congress. However, before submitting the legislation, the President must: (1) obtain an ITC assessment of the probable economic effect of the agreement; (2) submit a list of required changes to U.S. law to comply with the agreement; and (3) submit a statement of administrative action proposed to implement the TPP.15 Once the bill is introduced, Congress has 90 days to pass or reject the legislation, during which time the bill must get through the House Ways and Means and Senate Finance Committees, and each house of Congress must vote to approve it.16 If Congress passes the TPP and the President signs it, the TPP takes effect only after the President notifies Congress and all TPP member countries that U.S. law conforms with the TPP.

In light of widespread criticism, it may not be easy to win congressional approval of the TPP.17 Separate from other political issues concerning the effect of the TPP, members of Congress have expressed support for strong intellectual property protections, and specifically a twelve-year period of data exclusivity for biologics.18 Most notably, Senator Orrin Hatch, who chairs the Senate Finance Committee, had demanded strong protections for American pharmaceutical products, including biologics.19 Thus, it is still unclear as to whether biologics in the United States will lose their current twelve years of exclusivity.

Since reaching an agreement on October 5, 2015, the member countries have been drafting the final text. Much of the pharmaceutical industry has expressed disappointment that the TPP would not mandate a twelve-year exclusivity period.20 However, manufacturers of biosimilars have applauded the five-year period as balancing patient access and economic growth.21 The ultimate effect of the TPP internationally is still unclear and will be contingent on the final text of the agreement.

1 James Glenday and Anna Vidot, "Trans-Pacific Partnership: '50/50' chance of trade deal today as negotiators lock horns over medical patent protection," ABC News Australia (Oct., 4, 2015, 11:17 PM), http://www.abc.net.au/news/2015-10-05/pharmaceutical-patent-protection-deal-to-end-tpp-talks/6826956.

2 U.S. Chamber of Commerce, GIPC International IP Index 102 (3d ed. 2015), http://www.theglobalipcenter.com/wp-content/themes/gipc/map-index/assets/pdf/Index_Map_Index_3rdEdition.pdf.

3 Randi Hernandez, "Patent Exclusivity for Biologics: Seven or Twelve Years?", BioPharm International (Jan. 30, 2015), http://www.biopharminternational.com/patent-exclusivity-biologics-seven-or-twelve-years.

4 Brookings Institution, "Health policy 101: How the Trans-Pacific Partnership will impact prescription drugs," Health360 Blog (May 19, 2015, 11:20 AM), http://www.brookings.edu/blogs/health360/posts/2015/05/19-trans-pacific-partnership-prescription-drugs.

5 Alejandro Luna, "Mexico Issues Regulations to Approve Biologic Drugs," Olivares, http://www.olivares.com.mx/En/Knowledge/Articles/PatentArticles/Mexicoissuesregulationstoapprovebiologicdrugs (last visited Oct. 13, 2015).

6> U.S. Chamber of Commerce, GIPC International IP Index 66 (3d ed. 2015), http://www.theglobalipcenter.com/wp-content/themes/gipc/map-index/assets/pdf/Index_Map_Index_3rdEdition.pdf.

7 Michael Mezher, Trade Talks Stumble Over Biologics Data Exclusivity, Regulatory Affairs Professionals Society (Feb. 11, 2015), http://www.raps.org/Regulatory-Focus/News/2015/02/11/21309/Trade-Talks-Stumble-over-Biologics-Data-Exclusivity/.

8 Brett Norman and Sarah Karlin, "Pharma's Next Steps on TPP," Politico (Oct. 12, 2015, 12:02 PM), http://www.politico.com/tipsheets/prescription-pulse/2015/10/pharmas-next-steps-on-tpp-210674.

9 Zachary Brennan, Leaked TPP Chapter on IP Sets Terms of Biologics Data Exclusivity, Regulatory Affairs Professionals Society (Oct. 9, 2015), http://www.raps.org/Regulatory-Focus/News/2015/10/09/23363/Leaked-TPP-Chapter-on-IP-Sets-Terms-of-Biologics-Data-Exclusivity/

10 Transcript, U.S. Trade Representative, Trans-Pacific Partnership Atlanta Ministerial Closing Press Conference (Oct. 5, 2015).

11 Randi Hernandez, "TPP Discussions Conclude; Biologics Now Have Shorter Data Protection Periods," BioPharm International (Oct. 8, 2015), http://www.biopharminternational.com/tpp-discussions-conclude-biologics-now-have-shorter-data-protection-periods.

12 Jane M. Smith et al., Why Certain Trade Agreements Are Approved as Congressional-Executive Agreements Rather Than Treaties (CRS Report No. RL97896) (Washington, DC: Congressional Research Service, 2013).

13 Id.

14 Ian F. Fergusson, Trade Promotion Authority (TPA) and the Role of Congress in Trade Policy (CRS Report No. RL33743) (Washington, DC: Congressional Research Service, 2015) 22.

15 Bipartisan Congressional Trade Authorities and Accountability Act of 2015 19 U.S.C. § 4202

16 Fergusson, 22.

17 Zachary Brennan, Final TPP Agreement Draws Ire from Both Sides over Biologics Exclusivity, Regulatory Affairs Professionals Society (Oct. 5, 2015), http://www.raps.org/Regulatory-Focus/News/2015/10/05/23325/Final-TPP-Agreement-Draws-Ire-from-Both-Sides-over-Biologics-Exclusivity/.

18 Note to Media on Elected Officials Support for 12 Years of Data Protections in TPP, http://phrma.org/note-media-elected-officials-support-12-years-data-protection-tpp.

19 Hatch, Orrin, Hatch Calls for TPA Passage, Seeks Strong Outcomes on Trade Deals in Speech at American Enterprise Institute, Orrin Hatch United States Senator for Utah (Jan. 30, 2015), http://www.hatch.senate.gov/public/index.cfm/2015/1/hatch-calls-for-tpa-passage-seeks-strong-outcomes-on-trade-deals-in-speech-at-american-enterprise-institute.

20 BIO Statement on Data Exclusivity Provisions Within the Trans-Pacific Partnership, Biotechnology Industry Organization (Oct. 4, 2015), https://www.bio.org/media/press-release/bio-statement-data-exclusivity-provisions-within-trans-pacific-partnership.

21 Statement by Chip Davis, President and CEO, GPhA, Regarding the Trans-Pacific Partnership Agreement, Generic Pharmaceutical Association (Oct. 5, 2015), http://www.gphaonline.org/gpha-media/press/statement-by-chip-davis-president-and-ceo-gpha-regarding-the-trans-pacific-partnership-agreement.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
18 Sep 2018, Webinar, Washington, DC, United States

The program will examine lessons learned through CCPA and early Federal Circuit decisions and offer strategies to overcome the challenges of §112. For more information, or to register, please see Strafford Publications’ website.

23 Sep 2018, Seminar, Chicago, United States

Finnegan is a sponsor of the Intellectual Property Owners Association Annual Meeting, supporting the Women in IP Networking Brunch.

26 Sep 2018, Webinar, Washington, DC, United States

This latest series of webinars will explore emerging trends in the changing intellectual property (IP) legal environment in Europe and the United States.

 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions